News

Catch Up on Coverage From Day 1 of the 3rd Annual Elevate-Derm Summer Conference

Dermatology Times is looking back on the top stories in dermatology from the month of July.

In the latest episode of Don't Be Rash, host Andrew Krakowski, MD, is joined by Raegan D. Hunt, MD, PhD, to discuss newborn skin barrier development, umbilical cord care, and evidence-based product selection.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of July.

Phase 1 results show Bambusa Therapeutics’ BBT001 quickly reduces atopic dermatitis and itch, sustains type 2 biomarker suppression, and may enable quarterly dosing.

As we wrap up July, explore the new sunscreen ingredient approval, debunk summer skin care myths, and learn how UV damage and therapies are shaping skin cancer prevention today.

Our July issue tackles melanoma surgery challenges, melasma in skin of color, new bemotrizinol sunscreen, atopic dermatitis breakthroughs, and billing insights from Whitney Hovenic, MD, Joseph Gatti, DMSc, Rivkah Epstein, PA-C, and more.

Linda Stein Gold, MD, presents tapinarof cream as a long-term, nonsteroidal option for pediatric atopic dermatitis based on data presented at the 2026 Society for Pediatric Dermatology Annual Meeting.

Catch up on all of our coverage from this year's Society for Pediatric Dermatology annual meeting.

Learn from Adnan Mir, MD, PhD, on how better biopsies and direct lab communication help APPs and dermatopathologists boost pediatric skin diagnoses and outcomes.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Lawrence Eichenfield, MD, presented phase 3 results showing lebrikizumab boosts skin clearance, eases itch, and looks safe for infants through teens with moderate to severe atopic dermatitis.

A panel at SPD 2026 emphasized how pediatric dermatologists tackle pay gaps using RVU benchmarks, private practice options, and coding tactics to raise reimbursement.

Live from SPD 2026; learn how dermatologists can spot teen body dysmorphia, avoid reassurance traps, and use quick in-clinic tools to trigger early mental health referral.

Pediatric vitiligo care now prioritizes comorbidity screening like thyroid checks and anemia evaluation, mental health support, and new therapies including JAK trials and phototherapy options.

Linda Stein Gold, MD, discusses pooled phase 3 tapinarof cream data across pediatric atopic dermatitis age groups presented at the 2026 Society for Pediatric Dermatology meeting.

Pediatric histiocytosis updates at SPD 2026 reveal BRAF/MEK targets as dermatopathology and biopsy genetics boost accuracy in complex childhood dermatoses.

Honored with a top pediatric dermatology award, Amy Paller, MD, MS, shares her mentorship roots, career highlights, and continued advocacy for new treatments and research.

Sarah Chamlin, MD, and Jonathan Dyer, MD, shared practical guidance on treating ulcerated infantile hemangiomas and assessing café-au-lait spots, emphasizing pain control, propranolol, follow-up, and genetics.

Sanofi will not submit the OX40-ligand antibody for regulatory review, citing efficacy and safety data insufficient to improve upon current standard-of-care treatments for moderate to severe AD.

In his session at SPD, Markus Boos, MD, PhD showed how inclusive language, privacy, and team training improve dermatologic care and outcomes for gender minority youth.

Nanette Silverberg, MD, shares new pediatric vitiligo guidance, spotlighting facial-first goals, topicals, UVB, and steroid "rescue" strategies for widespread, fast-moving disease.

At SPD 2026, Brandi Kenner-Bell, MD, FAAD, shared practical pediatric dermatology tips for curly and coily hair: cleanse smarter, deep condition, avoid damaging chemicals, and reduce braid tension to prevent breakage.

Pediatric dermatology experts will gather in Minneapolis for SPD's Annual Meeting: will you be there?

In this episode, Renata Block, DMSCc, MMS, PA-C, discusses the new ICD-10 code for topical steroid withdrawal with Kelly Barta, the president and executive director of the International Topical Steroid Awareness Network.

New trends around cheeky swimwear and tanning myths are leading to rising rates of melanomas in sensitive areas; read July's cover story to learn more.

Long-term TNF inhibitor use was associated with significantly increased risks of melanoma and nonmelanoma skin cancer in a large cohort study.

This review of the latest dermatological studies includes insights on the burden of flooding, finasteride versus dutasteride in AGA, myocardial dysfunction in psoriasis patients, and more.

Dermatologists and oncologists at a Dermatology Times Evolving Paradigms event in Boston compared immunotherapy selection, referral practices and surveillance strategies in advanced cutaneous squamous cell carcinoma.

Derm Dispatch host Renata Block, DMSCc, MMS, PA-C, and Kelly Barta, president and executive director of the International Topical Steroid Awareness Network, discuss the new ICD-10 code for topical steroid withdrawal and ITSAN's international patient registry.